De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
ICPT Overzicht aandelen
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 4/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
Intercept Pharmaceuticals, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$19.00 |
| 52 Week Hoogtepunt | US$21.86 |
| 52 Week Laag | US$8.82 |
| Bèta | 0.88 |
| 11 maand verandering | 1.99% |
| 3 maanden verandering | 81.30% |
| 1 Jaar Verandering | 19.12% |
| 33 jaar verandering | -50.68% |
| 5 jaar verandering | -81.17% |
| Verandering sinds IPO | -2.06% |
Recent nieuws en updates
Recent updates
Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive
Jun 08
Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?
Apr 11Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?
Dec 20Intercept touts Ocaliva benefit in transplant-free survival in liver disease type
Sep 20Intercept cuts debt further with deal to exchange convertible notes
Sep 02Intercept reduces debt with repurchases of $327.9M convertible notes
Aug 19Intercept Pharmaceuticals: Too Risky To Buy At This Stage
Aug 13Intercept Pharma Q2 2022 Earnings Preview
Aug 02Intercept to resubmit for FDA approval of NASH candidate after new analysis
Jul 07Intercept: Increase Of Ocaliva Sales And A Few Catalysts
May 23Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
May 10Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH
Mar 05Intercept names Andrew Saik as chief financial officer
Jun 07Intercept Pharmaceuticals slides as FDA restricts Ocaliva use
May 26Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Are Analysts Optimistic?
May 11Rendement voor aandeelhouders
| ICPT | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 0.1% | -0.5% | 0.1% |
| 1Y | 19.1% | 18.4% | 32.2% |
Rendement versus industrie: ICPT overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 21.7 % opleverde.
Rendement versus markt: ICPT overtrof de US markt, die het afgelopen jaar een rendement opleverde van 33.4 %.
Prijsvolatiliteit
| ICPT volatility | |
|---|---|
| ICPT Average Weekly Movement | 22.8% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: De aandelenkoers van ICPT is de afgelopen 3 maanden volatiel geweest.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van ICPT is het afgelopen jaar gestegen van 15% naar 23%.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2002 | 341 | Jerry Durso | www.interceptpharma.com |
Intercept Pharmaceuticals, Inc. Samenvatting
| ICPT fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$794.69m |
| Inkomsten(TTM) | -US$57.47m |
| Inkomsten(TTM) | US$317.68m |
2.5x
P/S-verhouding-13.8x
Koers/WinstverhoudingIs ICPT overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ICPT resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$317.68m |
| Kosten van inkomsten | US$632.00k |
| Brutowinst | US$317.05m |
| Overige uitgaven | US$374.52m |
| Inkomsten | -US$57.47m |
Laatst gerapporteerde inkomsten
Sep 30, 2023
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -1.37 |
| Brutomarge | 99.80% |
| Nettowinstmarge | -18.09% |
| Schuld/Eigen Vermogen Verhouding | 311.6% |
Hoe presteerde ICPT op de lange termijn?
Bekijk historische prestaties en vergelijking